Insider Trading Alert - BID, FMER And GEVA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, March 7, 2014, 162 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $252.67 to $79,694,022.59.

Highlighted Stocks Traded by Insiders:

Sothebys (BID) - FREE Research Report

Dodge Steven B who is Director at Sothebys bought 194 shares at $39.70 on March 7, 2014. Following this transaction, the Director owned 26,791 shares meaning that the stake was reduced by 0.73% with the 194-share transaction.

The shares most recently traded at $48.17, up $8.47, or 17.58% since the insider transaction. Historical insider transactions for Sothebys go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 211
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 211
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 211

The average volume for Sothebys has been 1.3 million shares per day over the past 30 days. Sothebys has a market cap of $3.2 billion and is part of the services sector and specialty retail industry. Shares are down 11.79% year-to-date as of the close of trading on Friday.

Sotheby's operates as an auctioneer of authenticated fine art, decorative art, and jewelry. The company operates in three segments: Auction, Finance, and Dealer. The stock currently has a dividend yield of 0.85%. The company has a P/E ratio of 25.0. Currently there are 2 analysts that rate Sothebys a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on BID - FREE

TheStreet Quant Ratings rates Sothebys as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Sothebys Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Firstmerit (FMER) - FREE Research Report

Brocklehurst N. James who is Executive Vice President at Firstmerit sold 4,673 shares at $21.15 on March 7, 2014. Following this transaction, the Executive Vice President owned 38,857 shares meaning that the stake was reduced by 10.74% with the 4,673-share transaction.

The shares most recently traded at $21.69, up $0.54, or 2.49% since the insider transaction. Historical insider transactions for Firstmerit go as follows:

  • 4-Week # shares sold: 8,863
  • 12-Week # shares sold: 8,863
  • 24-Week # shares sold: 30,905

The average volume for Firstmerit has been 1.3 million shares per day over the past 30 days. Firstmerit has a market cap of $3.5 billion and is part of the financial sector and banking industry. Shares are down 3.96% year-to-date as of the close of trading on Friday.

FirstMerit Corporation operates as a bank holding company for FirstMerit Bank, N.A. that provides various banking, fiduciary, financial, insurance, and investment services to corporate, institutional, and individual customers. The stock currently has a dividend yield of 3%. The company has a P/E ratio of 18.1. Currently there are 7 analysts that rate Firstmerit a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FMER - FREE

TheStreet Quant Ratings rates Firstmerit as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, compelling growth in net income and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Firstmerit Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Synageva BioPharma (GEVA) - FREE Research Report

Baker Julian who is Director at Synageva BioPharma bought 375,000 shares at $105.75 on March 7, 2014. Following this transaction, the Director owned 211,614 shares meaning that the stake was reduced by 229.52% with the 375,000-share transaction.

Baker Felix who is Director at Synageva BioPharma bought 375,000 shares at $105.75 on March 7, 2014. Following this transaction, the Director owned 211,614 shares meaning that the stake was reduced by 229.52% with the 375,000-share transaction.

The shares most recently traded at $98.78, down $6.97, or 7.06% since the insider transaction.

The average volume for Synageva BioPharma has been 261,700 shares per day over the past 30 days. Synageva BioPharma has a market cap of $3.0 billion and is part of the health care sector and drugs industry.

Synageva BioPharma Corp., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical needs. Currently there are 5 analysts that rate Synageva BioPharma a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GEVA - FREE

TheStreet Quant Ratings rates Synageva BioPharma as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Synageva BioPharma Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options

All Investors Can Trade Options, Just Ask the Najarian Brothers WATCH VIDEO

All Investors Can Trade Options, Just Ask the Najarian Brothers WATCH VIDEO

Dow Makes Move Higher as Bond Yields Hover Near 3% Threshold

Dow Makes Move Higher as Bond Yields Hover Near 3% Threshold

Aluminum Prices Plummet as U.S. Is Open to Easing Sanctions on Russia's Rusal

Aluminum Prices Plummet as U.S. Is Open to Easing Sanctions on Russia's Rusal

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations